Prostate Cancer Clinical Trial
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
Summary
This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Studying quality of life in patients undergoing stereotactic body radiation therapy may help identify the long-term effects of treatment on patients with prostate cancer.
Full Description
PRIMARY OBJECTIVES:
I. To establish the efficacy of stereotactic body radiation therapy (SBRT) in patients with high-risk localized prostate cancer compared to historical data from clinical trials.
II. To establish the safety with physician-reported outcomes after SBRT in patients with high risk localized prostate cancer.
III. To establish the quality of life with patient-reported validated questionnaires after SBRT in patients with high risk localized prostate cancer.
OUTLINE:
Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
After completion of study treatment, patients are followed up every 4 months for 1 year, every 6 months for 5 years, and then every 12 months thereafter.
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
Risk-group classification into the D’Amico or National Comprehensive Cancer Network (NCCN) ‘high-risk’ group, as defined by the presence of any one of the following high-risk factors:
Pre-biopsy prostate-specific antigen (PSA) >= 20
Biopsy Gleason score 8-10
Clinical stage T3
No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance imaging [MRI] findings)
No distant metastases, based upon:
CT scan or MRI of the pelvis within 120 days prior to registration
Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis
Karnofsky performance status (KPS) >= 70
Ability to understand, and willingness to sign, the written informed consent
Patient will have opted for SBRT among definitive treatment choices
Exclusion Criteria:
Patients with any evidence of distant metastases
Hormonal therapy (luteinizing hormone-releasing hormone [LHRH] agonist or oral anti-androgen) exceeding 4 months prior to registration
Prior cryosurgery, high intensity focused ultrasound (HIFU) or brachytherapy of the prostate
Prior pelvic radiotherapy
History of Crohn’s disease or Ulcerative colitis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, 90095, United States
How clear is this clinincal trial information?